Aptadir Therapeutics is developing a treatment for Myelodysplastic Neoplasms based on the capability of specific RNA therapeutics.
Aptadir Therapeutics has raised $45.5M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
Aptadir Therapeutics's investors include CDP Venture Capital, XGEN Venture, 4BIO Capital, Evotec, Indaco Venture Partners.
Aptadir Therapeutics is headquartered in Milan, Italy.
Aptadir Therapeutics is developing a treatment for Myelodysplastic Neoplasms based on the capability of specific RNA therapeutics.
Aptadir Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aptadir Therapeutics — Funding & Investors." VCBacked, September 29, 2026, https://www.vcbacked.co/company/aptadir-therapeutics. Accessed October 17, 2026.
VCBacked. (2026). Aptadir Therapeutics — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/aptadir-therapeutics
{{cite web |title=Aptadir Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aptadir-therapeutics |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated